Close Menu

NEW YORK — Guardant Health said on Monday that it is collaborating with Amgen to develop and commercialize a global blood-based companion diagnostic test for the pharmaceutical firm's investigational oral therapy AMG 510, which inhibits KRAS G12C mutant protein.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.